Scleroderma, Systemic, Fibrosis, Semaglutide
Conditions
Brief summary
This trial will study the safety and efficacy of subcutaneous semaglutide for the treatment of Systemic Sclerosis
Detailed description
Systemic Sclerosis (Ssc) is a rare, systemic autoimmune disease characterized by skin fibrosis and vasculopathy. In addition to the skin, it is a heterogeneous disease that affects multiple organs, including the cardiac, pulmonary, and gastrointestinal systems. This is a small prospective and open-label clinical trial of semaglutide in adults with systemic slceorsis. 10 systemic sclerosis patients will be recruited and receive semaglutide for 24 weeks. The primary endpoint of the study is the change in mRSS at 24 weeks of treatment.
Interventions
Inject semaglutide subcutaneously once weekly, on the same day each week, at any time of day, in a dose increasing mode: the initial dose of 0.25mg QW (once a week), increased to 0.5mg QW after 4 weeks, and then maintained 0.5mg until the end of treatment in total 24 weeks.
Sponsors
Second Xiangya Hospital of Central South University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
(Those who have not achieved good results after hormone or immunosuppressive therapy) 1. Gender unlimited; 2. Age 18-65 years old (including 65 years old); 3. Patients diagnosed with SSc who meet the 2013 European Union Against Rheumatology (EULAR)/American Society of Rheumatology (ACR) SSc diagnostic classification criteria and exclude infections, tumors, and other connective tissue diseases. 4. Has received one or more of the following standard systemic treatments allowed by the research protocol: 1. Before the first subcutaneous injection of the study, oral corticosteroids (prednisone not exceeding 15mg/d or equivalent) were administered for ≥ 8 weeks, and stabilizers were administered for ≥ 4 weeks. 2. Before the first subcutaneous injection of the study, patients were treated with Tofacitinib (5-10mg/d) for ≥ 8 weeks and received a stabilizer dose for ≥ 6 weeks. 3. If one or more of the following immune modulators are used, treatment must be given for ≥ 12 weeks before the start of the study, and treatment with a stabilizer dose must be given for ≥ 6 weeks Oral mycophenolate mofetil (MMF) ≤ 1.5 g/day Methotrexate (MTX) oral ≤ 15 mg/week, combined with folic acid Cyclosporine If the subjects use ≥ 2 of the above immunomodulatory drugs in combination, the appropriateness of the subjects' participation in the study must be discussed with the medical supervisor and study chair before enrollment. 5. A modified Rodnan Skin Score (mRSS) of \> 14 6. Those who sign an informed consent form, voluntarily participate in this project, and are able to complete follow-up as required.
Exclusion criteria
1. Prior to the first dose, Body Mass Index (BMI) \< 18.5 kg/m2; weight loss of 10% within one month or 20% within six months. 2. Family or personal history of type 2 multiple endocrine neoplasia or medullary thyroid carcinoma, with family history involving first-degree relatives. 3. History of malignant tumors or a history of malignant tumors within the past 5 years before screening. 4. Presence of other inflammatory diseases that may interfere with efficacy assessment, including but not limited to rheumatoid arthritis (RA), overlap syndrome, psoriasis, dermatomyositis, multiple sclerosis, Crohn's disease, or active Lyme disease. 5. Severe gastrointestinal complications of systemic sclerosis (SSc), such as significant swallowing difficulties, and severe diseases affecting vital organ systems such as the heart, brain, lungs, liver, kidneys, or blood, as deemed unsuitable for participation in the study by the investigator. 6. Known current active or recurrent severe infections, including active tuberculosis. 7. Congenital immunodeficiency or congenital immunosuppression. 8. Substance abuse, alcoholism, or psychiatric disorders, rendering patients uncooperative or unable to adhere to treatment; poor predictability of compliance. 9. Women who are pregnant, breastfeeding, or planning to become pregnant. 10. Patients currently participating in other clinical trials.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in modified Rodnan skin score (mRSS) at week 24 | Baseline and 24 weeks | Change in modified Rodnan skin score (mRSS) at week 24 performed by the same investigator at week 0 and week 24 and the change in mRSS will be calculated following the formula: ΔmRSS= mRSSw24 - mRSSw0. To measure mRSS, skin thickness of the patient is rated by palpation at each of 17 anatomic sites using a scale of 0-3 (0 = normal skin; 1= mild thickness; 2= moderate thickness; 3=severe thickness with an inability to pinch the skin into a fold). The scores at each site are summed with a minimum of 0 and a maximum of 51 (17 sites) |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of Adverse Events | Baseline and 24 weeks |
| the scleroderma health assessment questionnaire-disability index (sHAQ-DI) | Baseline and 24 weeks |
| High-resolution computer tomography (HRCT) | Baseline and 24 weeks |
| Forced Vital Capacity(FVC) and Diffusing capacity of the lung for carbon monoxid(DLCO) | Baseline and 24 weeks |
| Incidence of Severe Adverse Events | Baseline and 24 weeks |
| Pulmonary arterial hypertension by echocardiography | Baseline and 24 weeks |
| left ventricular ejection fraction by echocardiography | Baseline and 24 weeks |
| 6-Minute Walk Test (6MWT) Distance | Baseline and 24 weeks |
| gastrointestinal tract (GIT) in scleroderma score | Baseline and 24 weeks |
| St George' s Respiratory Questionnaire(SGRQ) | Baseline and 24 weeks |
Countries
China
Contacts
Primary ContactRong Xiao, MD
Backup ContactLicong Liu, MD
Outcome results
None listed